Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Co Inc (NYSE:MRK) shares, reducing the pharmaceutical giant's price target from $130.00 to $122.00 while reaffirming a Buy rating on the stock. The revision by Guggenheim analyst is primarily due to ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Happy New Year, biotech friends! We’re back with news, including Merck’s decision to cut the price of its diabetes drug Januvia by 42% and Neumora’s readout on its experimental depression drug.

On January 1, pharmaceutical companies will also lower some of their prices. The list price of Merck & Co.'s heavily discounted diabetes medications Januvia and Janumet will be lowered "to align the ...

(Journal of Clinical Endocrinology & Metabolism) At the start of the new year, Merck plans to cut the list price of its diabetes drugs sitagliptin (Januvia) and sitagliptin/metformin (Janumet ...

Januvia, and Bridion. It also provides vaccines for various age groups under brands such as Gardasil and Pneumovax. Merck & Co., Inc. (NYSE:MRK) has recently partnered with the Chinese biopharma ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet ...

Merck will discontinue its antibody-drug Zinplava for a bacterial infection that can lead to fatal diarrhea, according to the U.S. Food and Drug Administration's website. Zinplava, first approved by ...